Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can Thrombin Pathway Be a New Target for Therapy?

摘要

Although contemporary cardiovascular treatment strategies including antiplatelet agents and statins have improved the clinical outcomes in high-risk patients with atherosclerotic cardiovascular disease (ASCVD), the mortality rate from ischemic heart disease remains unchanged and up to 5% of patients suffered from recurrent CV events each year. Therefore, novel therapeutic strategies are required to prevent adverse clinical events.